Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
| Autor: | Ritva Koskela, Clas-Göran af Björkesten, Jyrki Tillonen, Christian Nielsen, M Koivunen, Erkki Soini, Taru Hallinen, Ilkka Vihriälä, Airi Jussila, Ulla-Maija Suhonen, C Wennerström, Karri T Utriainen, Inka Koskinen, Kalle Hakala, R Nissinen, Tuire Ilus, Andras Borsi, Heikki Nuutinen, Markku Heikkinen, Veikko Moilanen, Taina Sipponen, Urpo Nieminen, Anja Eberl, Mikko Heikura |
|---|---|
| Přispěvatelé: | HUS Abdominal Center, Gastroenterologian yksikkö, University of Helsinki, Helsinki University Hospital Area, HYKS erva, Päijät-Häme Welfare Consortium |
| Rok vydání: | 2020 |
| Předmět: |
Crohn’s disease
Adult MAINTENANCE THERAPY medicine.medical_specialty Crohn’ Original Articles: Gastroenterology Disease calprotectin simple endoscopic score for Crohn’s disease Inflammatory bowel disease ustekinumab endoscopic healing s disease 03 medical and health sciences 0302 clinical medicine Crohn Disease Maintenance therapy inflammatory bowel disease Internal medicine Ustekinumab medicine Humans biologics Crohn’ s disease Finland Retrospective Studies OUTCOMES Crohn's disease Hepatology business.industry INDUCTION Remission Induction Gastroenterology simple endoscopic score for Crohn’ biomarkers medicine.disease Faecal calprotectin 3. Good health simple endoscopic score for Crohn’ s disease Pharmaceutical Preparations 3121 General medicine internal medicine and other clinical medicine 030220 oncology & carcinogenesis Cohort 030211 gastroenterology & hepatology 3111 Biomedicine Calprotectin business medicine.drug |
| Zdroj: | European Journal of Gastroenterology & Hepatology |
| ISSN: | 0954-691X |
| Popis: | Objective: Long-term evidence on ustekinumab treatment response and persistence in patients with Crohn’s disease in a real-world setting is scarce. We performed a retrospective nationwide chart review study of long-term clinical outcomes in Crohn’s disease patients treated with ustekinumab. Methods: The study was conducted in 17 Finnish hospitals and included adult Crohn’s disease patients who received an initial intravenous dose of ustekinumab during 2017–2018. Disease activity data were collected at baseline, 16 weeks, and 1 year from health records. Results: The study included 155 patients. The disease was stricturing or penetrating in 69 and 59% had prior Crohn’s disease-related surgeries, and 97% had a treatment history of at least one biologic agent. Of 93 patients with ≥1 year of follow-up, 77 (83%) were still on ustekinumab at 1 year. In patients with data available, from baseline to the 1-year follow-up the simple endoscopic score for Crohn’s disease (SES-CD) decreased from 10 to 3 (P = 0.033), C-reactive protein from 7 to 5 mg/L, (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|